See our exclusive index of companies on the move:
Explore Stocks- Top Stocks
- Top Australian Gold Stocks
- Top ASX Copper Stocks
- Top ASX Nickel Stocks
- Top ASX Rare Earth Stocks
- Top Battery Metals Stocks on the ASX
- Top Australian Lithium Stocks
- Top Graphite Miners on the ASX
- 10 ASX Cannabis Stocks
- Top ASX Tech Stocks
- Top AI Stocks on the ASX
- On Site
- About Australian Cannabis Investing
- About Australian Resource Investing
- About Australian Tech Investing
- About Australia Investing
- Of Interest
- ASEAN-Australia-New Zealand Trade Agreement
- Association of Southeast Asian Nations (ASEAN)
- Australian FAQ on ASEAN
- Australia Government on Foreign Investments

Using CBD for pets is becoming increasingly popular. Here's a look at whether it's legal in Australia and what CBD can really do for animals.
The medicinal cannabis market is strengthening in Australia, and the country has grand plans of growing, retailing and exporting cannabidiol (CBD) to a keen market.
Among its many applications, CBD is seen as a medicinal aid for people — but what about for pets?
CBD is gaining traction as a remedy for pet ailments as part of an overall treatment plan for chronic illnesses. Read on to learn more about CBD for pets in Australia, from legality to how it can help animals.
What is CBD and is it legal in Australia?
Products containing low doses of CBD are considered safe and legal, provided they have been approved by the Australian Register of Therapeutic Goods (ARTG).
This is a fairly new development — on February 1, 2021, it became legal to purchase low-dose CBD products over the counter at the pharmacist. This change signalled a reclassification of CBD from Australia's Therapeutic Good Administration; it went from being a Schedule 4 product (prescription medicine) to a Schedule 3 product (pharmacist-only medicine).
The catch is that so far no product has yet been approved by the ARTG — unlike other nations that have differing state laws, or even classify CBD as a dietary supplement, in Australia the classification of CBD as medicine has created a lengthy path for approval. Still, CBD is theoretically a legal substance in Australia.
Because of these circumstances, owners who want to source CBD for their pets will need their vet to prescribe the substance. This can be done providing the product to be used meets four conditions:
- Cannabidiol comprises 98 percent or more of the total cannabinoid in the preparation.
- Any cannabinoids other than cannabidiol must be only those naturally found in cannabis.
- The owner must consent to trial an unlicenced and potentially harmful treatment.
- There is adequate monitoring of the furry patient's response and any side effects.
The process can be tricky, but there are dedicated businesses set up purely to facilitate the process of obtaining legal medicinal CBD for pets — like CBD Vets Australia.
How can CBD help pets?
Through anecdotal data and information, CBD is thought to be able to assist pets with a number of conditions, such as epilepsy, arthritis, stress and anxiety, chronic pain and nausea; it can even help them sleep.
CBD is an antidote for owners looking to soothe their pets' ailments and keep them both calm and free of pain. As it comes in both capsule and liquid forms, it can be easily mixed in pet food.
In terms of CBD pet products currently available in Australia, animals could access the same CBD oil as humans as of the time of publication.
Importantly, CBD is not to be confused with hemp products. Hemp products, including creams and edible oil, contain extremely low forms of THC cannabis, but are considered to be a safe and legal food product — they are particularly high in omega 3 and six fatty acids.
What's the outlook for Australia's CBD pet products market?
It is early days for the CBD pet market in Australia, and more research is needed on the impacts and effects of CBD on our four-legged companions.
There is positive anecdotal feedback on its benefits, but further information is needed to allow a greater number of vets to feel comfortable prescribing CBD to pets.
The industry has seen growth in medicinal cannabis prescriptions in Australia, and it's possible that the same movement will start to be seen in the pet niche over the coming years, making it a potential avenue for investors to keep an eye on. For now, click the links below for more on Australia's CBD market:
Don't forget to follow @INN_Australia for real-time updates!
Securities Disclosure: I, Ronelle Richards, hold no direct investment interest in any company mentioned in this article.
VIDEO — Joe Mazumdar: Good vs. Bad Financings — What to Look for When Juniors Raise Money
Joe Mazumdar of Exploration Insights also shared his thoughts on the copper market and how to evaluate copper deposits.
Joe Mazumdar: Good vs. Bad Financings — What to Look for When Juniors Raise Money youtu.be
Raising money is a key challenge for juniors in today's markets — and even when companies are able to secure funds, it's key to remember that not all financings are equal.
Speaking at the Prospectors & Developers Association of Canada (PDAC) convention, Joe Mazumdar, editor of Exploration Insights, shared his thoughts on how investors can differentiate between good and bad financings.
Along with considerations like warrants, he told the Investing News Network that before buying shares of an exploration company it's a good idea to look at when it last went to market.
"With Canadian financings — not Australian or anything like that — they have a four month hold, so those people might sell four months later," he explained. "And so if you're looking (for a good time to come in), hold back, wait for the four month hold to be released, let them sell if they're going to sell and then come in on the back side."
Mazumdar also pointed to share structure, saying it can cause problems even for good assets.
"The share structure is very important, because we've got to take that asset and stick it in that share structure," he said. "And so if the share structure is not very good, it doesn't really matter what the quality of the asset is, because you'll probably lose out in terms of your share price increase, because they'll constantly dilute."
In his opinion, juniors that raised extra money in 2021 are now better positioned than those that only raised enough for one season, which is what companies typically do.
"Some of them raised for two years, and now they don't have to worry about what's happening with the volatility in the current market because they're past that," Mazumdar said. "And so I think that trend of raising much more than you need is good given the volatility in the market if you're a non-cash-flowing company."
Watch the interview above for more from Mazumdar on the junior resource sector, as well as on copper. You can also click here for our recap of PDAC, and here for our full PDAC playlist on YouTube.
Don't forget to follow us @INN_Resource for real-time updates!
Securities Disclosure: I, Charlotte McLeod, hold no direct investment interest in any company mentioned in this article.
Editorial Disclosure: The Investing News Network does not guarantee the accuracy or thoroughness of the information reported in the interviews it conducts. The opinions expressed in these interviews do not reflect the opinions of the Investing News Network and do not constitute investment advice. All readers are encouraged to perform their own due diligence.
Building a globally diversified portfolio of companies in high-growth industries.
Overview
Hygrovest Limited (ASX:HGV) has a globally diversified portfolio focused on investing in private and public companies in high-growth industries. Hygrovest has investments in cannabis-focused companies and in December 2021, the company expanded their portfolio to include healthcare, natural resources, and the digital economy as well as e-sports, sports betting, online gaming, and fintech.
Hygrovest's diversified investment is managed by Parallax Ventures Inc. (“Parallax”), a specialist management company in Canada, under a long-term strategic partnership. The agreement with Parallax offers access to new investment opportunities, added material value to existing investments, minimised HGV’s fixed cost structure, and secured meaningful investment presence in HGV’s key investment market – North America.
Hygrovest's portfolio includes a portfolio of CBD and cannabis investments in cultivation, extraction and consumer products with material investments in Weed Me, WeedMD, Sequoya, Harvest One and Southern Cannabis Holdings.
Hygrovest operates a robust share purchase plan, which provides eligible shareholders the opportunity to invest in the portfolio at a 51 percent discount to net value assets. This attribute is exceptionally advantageous with the company's generation of substantial realized gains from its sale of Dosecann Inc. and Medipharm LABS, two Canadian cannabis-based companies providing leading cannabis technologies in extraction and product development.
A significant goal for Hygrovest's Board includes trading its share price at a premium to NAV, considering prospective returns from its high-quality portfolio companies. The company has seen positive trends in investment returns in the past five years and has generated a Multiple on Invested Capital (MOIC) of 1.3 times capital invested. Its mixture of private and listed companies across the emerging Australian and offshore cannabis and hemp markets primes the company for dominant standing as a major investment company.
Its highly-developed investment process includes active formulating, frequent reviewing, and effective investment best practices based on reliable valuation information. The Hygrovest Board operates as the final approval level for acquisition and the sale of investment proposals, which involve an exercise of rights attached to specific investments. Its current investment approval process operates based on Hygrovest's Investment Management Agreement with Parallax Ventures Inc, effective from 1 June 1 2019.
Future plans for the company involve focusing on U.S. investment expansion, employing liquidity into Canadian markets and developing its brands and distribution chains. The company notes significant attention towards its Harvest One Cannabis (TSXV:HVT) investee, which saw a 116 percent increase in value during February 2021, reaching totals of CAD$13.4 million.
"You can see with Harvest One, which is our largest investment, has a massive distribution network and has very high-quality plans coming along. We believe those types of investments in the long-term will be exceptionally attractive," commented Hygrovest Non Executive Director Michael Curtis.
Hygrovest Limited comprises a strong team with over 80 years of combined experience in investment banking, corporate strategy and cannabis fields. The company also benefits from having the Canadian-based Parallax Ventures Inc. on its Board as a strategic asset manager. Together, this leadership primes Hygrovest for significant success and growth with strategies to enhance acceleration and collaboration within the portfolio.
Company Highlights
- Hygrovest has a globally diversified portfolio that includes private and public companies in high-growth industries.
- Hygrovest has expanded their portfolio to include healthcare, natural resources, and the digital economy as well as e-sports, sports betting, online gaming, and fintech.
- Investment return in the past five years has generated a MOIC of 1.1 times the capital invested. This financial upside is amplified with the company's MOIC of 3.5 times on investments sold in that period including sales of Dosecann Inc. and Medipharm LABS.
- Hygrovest has a proven track record in acquiring and realizing significant value from its investments. They combine years of professional experience in investment banking, corporate governance and strategic acquisition.
- Harvest One Cannabis, Hygrovest's largest investment, saw a 116 percent increase in value totaling CAD$13.4 million in February 2021, presenting the company with exceptional growth potential.
- The company has a strong management team and benefits from having the Canadian-based Parallax Ventures Inc. on its board as its asset manager.
Hygrovest Limited operates a robust investment portfolio consisting of listed and private cannabis companies across a diverse variety of emerging cannabis-related sectors, including healthcare, technology, infrastructure, logistics, processing, cultivation, equipment and retail.
Current investment in its portfolio include:
- Harvest One Cannabis Inc. (CVE:HVT)
- Southern Cannabis Holdings
- Weed Me
- Martha Jane Medical
- Vitagenne
- Sequoya
- WeedMD Rx Inc. (CVE:WMD)
- Bespoke Capital Acquisition Corp.
Hygrovest 's portfolio of investments sold:
- BevCanna Enterprises Inc. (CNSX:BEV)
- Fire & Flower (TSE:FAF)
- MediPharm LABS (TSE:LABS)
- Hemple
- Axiomm Technologies
- Volero Brands Inc.
This portfolio leverages favorable market conditions with the majority of Canadian listed cannabis producer valuations seen dropping in 2020. Hygrovest intends to take advantage of this market backdrop and continue to create substantial investment opportunities, strategic partnerships and high-quality acquisitions.
Management Team
Peter Wall - Non- Executive Chairman
Peter Wall is a corporate lawyer and has been a partner at Steinepreis Paganin, a Perth-based corporate law firm, since July 2005. He has a wide range of experience in all forms of commercial and corporate law, with a particular focus on medical cannabis, resources, equity capital markets and mergers and acquisitions. He also has significant experience in dealing with cross-border transactions.
Wall graduated from the University of Western Australia in 1998 with a Bachelor of Laws and Bachelor of Commerce (Finance). He has also completed a Masters of Applied Finance and Investment with FINSIA.
Winton Willesee - Non-Executive Director
Winton Willesee is an experienced company director and brings a broad range of skills and experience in strategy, company development, corporate governance, company public listings, merger and acquisition transactions and corporate finance. He has considerable experience with ASX listed and other companies over a broad range of industries, having been involved with many successful ventures from early-stage through to large capital development projects.
Willesee holds formal qualifications in economics, finance, accounting, education and governance. He is a fellow of the Financial Services Institute of Australasia, a graduate of the Australian Institute of Company Directors, a member of CPA Australia and a fellow of the Governance Institute of Australia/Chartered Secretary.
Doug Halley - Non-Executive Director
Doug Halley is an experienced company director and has served for 30 years as CFO or CEO in several significant and successful commercial enterprises and investment banks. His executive experience had a heavy emphasis on corporate strategy, treasury, financial management, M&A and business development. As a professional director, Halley has developed risk management and governance expertise. He has a strong background in IPO and start-ups and a reputation for innovation, perseverance and achieving solutions and results.
Halley has a Bachelor of Commerce, Master of Business Administration and is a fellow of the Australian Institute of Company Directors.
Michael Curtis - Non-Executive Director
Michael Curtis resides in Toronto, Canada and is an experienced former investment banker and private equity executive. He is an active cannabis sector executive, having recently served as VP of Corporate Finance of Dosecann Inc. and Managing Partner of Parallax Ventures Inc. Curtis was previously the COO and Director of Embark Health Inc. and remains a consultant to Embark Health Inc.
Curtis has a Master of Business Administration from the University of New Brunswick, Bachelor of Sciences (Honors) from McMaster University.
Jim Hallam - CFO & Corporate Secretary
Jim Hallam has over 30 years of experience in the investment management industry with alternative asset fund managers in Australia and overseas, including Hastings Funds Management and Annuity Australia. His roles include acting as responsible manager, investment manager and Chief Financial Officer within alternative asset fund managers.
Hallam has a Bachelor of Commerce in Economics, is a member of the Chartered Accountants Australia and New Zealand and a fellow of the Governance Institute of Australia.
VIDEO — Peter Krauth: Silver's 2022 Price Path, "Wild Card" Demand Factor to Watch
"I think that (investment demand is) going to be kind of the wild card that could really push silver much higher," said Peter Krauth of Silver Stock Investor.
Peter Krauth: Silver Price in 2022, Can Anything Derail the Metal Now? youtu.be
Peter Krauth, editor of Silver Stock Investor, has a long-term silver price target of US$300 per ounce. But what does he see coming for the white metal in 2022?
Speaking at the Prospectors & Developers Association of Canada (PDAC) convention, Krauth said he thinks a realistic move for silver this year would be "to at least US$25, or a little bit north of US$25."
In his opinion, industrial demand will create a key price floor, while investment demand will be less predictable.
"I think that (investment demand is) going to be kind of the wild card that could really push silver much higher," Krauth explained. "People are going to get excited about gold, and they're going to look for an alternative."
When asked if there's anything that could derail the silver story, Krauth was candid: "There's one thing — the (US Federal Reserve) could start raising rates to 15 or 20 percent. And I think the odds of that are less than zero."
Although Krauth believes the best analogue for the current situation is the 1970s, he emphasized that inflation can't be solved the same way it was dealt with back then. He explained that the debt-to-GDP ratio was 35 percent during that decade, whereas now it is 130 percent. That means debt today is nearly four times what it was then.
"The Fed knows that it needs to raise rates in order to fight inflation, but it also knows that realistically it can't," said Krauth, who is also the author of the book "The Great Silver Bull."
As a breaking point approaches, he believes non-traditional portfolio elements like silver are key. "I really think the solution is to start looking at alternative assets," he said.
Watch the interview above for more from Krauth on silver. You can also click here for our recap of PDAC, and here for our full PDAC playlist on YouTube.
Don't forget to follow us @INN_Resource for real-time updates!
Securities Disclosure: I, Charlotte McLeod, hold no direct investment interest in any company mentioned in this article.
Editorial Disclosure: The Investing News Network does not guarantee the accuracy or thoroughness of the information reported in the interviews it conducts. The opinions expressed in these interviews do not reflect the opinions of the Investing News Network and do not constitute investment advice. All readers are encouraged to perform their own due diligence.
Australia's medical cannabis market is growing, with recreational legalisation and exports presenting future opportunities for savvy investors.
Australia’s cannabis market is young, but with new products coming online, a growing push toward recreational legalisation and increased clinical research, it could offer a unique investment opportunity.
Investors are eagerly awaiting the growth projected for the Australian cannabis space — with medical avenues now established, it shows signs of potentially moving into another phase with broader access.
Read on for a look at projections for the cannabis industry in Australia and what they may mean for investors.
Investing in cannabis stocks on the ASX: Market overview
Medical cannabis was legalised in Australia in 2016, when the Narcotic Drugs Act was amended. This move allowed the plant to be grown for medical and scientific purposes, and sparked movement in the industry.
Expansion is projected moving forward. In a recent report from Grand View Research, researchers state that the legal cannabis market in Australia is poised for large increases in the coming years. Valued at AU$51.8 million in 2021, this number is projected to rise at a compound annual growth rate of 30.1 percent until 2028.
However, in recent years the country has been hit by the slump dragging down cannabis markets across the world. Among other impacts, this has brought a drastic shift in international investment, with some Canadian firms adjusting their Australian expansion plans due to the conditions seen in the cannabis industry.
Despite the struggles seen in the stock market, the Australian cannabis industry has seen some pick-up thanks to the rush of new medical cannabis products becoming available to consumers.
According to a report from cannabis research firm FreshLeaf Analytics, during H2 2021, market growth exceeded expectations, and the country's patient count climbed to near 100,000.
“Although we note the early stage of the sector in Australia and the associated volatility of a nascent industry, over the same period patient numbers domestically have continued to soar,” the note explains.
The rise in patient approvals could be due to legislation put in place in New South Wales that loosened the requirements for prescribing medical cannabis. Now, unless a patient is under 16 years old or has a history of drug abuse, medical practitioners in the state can prescribe cannabis medicines without having to refer to a specialist.
There’s also been a decrease in pricing pressure for medical cannabis patients throughout the country, which is helping to boost access for consumers. FreshLeaf states that monthly spending from medical cannabis patients was down to AU$395 in 2019 from AU$415, and has since further dropped to AU$278.
Investing in cannabis stocks on the ASX: Avenues for growth
As Australia's medical cannabis market grows, other avenues for expansion are also opening.
Australia has seen an increased push to okay cannabis for recreational use since the Australian Capital Territory announced plans to legalise the drug in September 2019; it was the first region in the country to do so.
The new law came into effect on January 31, 2020, and allows individuals over 18 to possess up to 50 grams of dried flower and cultivate two cannabis plants in their home, with a maximum of four plants per residence.
However, no stores sell it, and the only legal means to acquire cannabis in the state is to personally grow it.
The Hemp Industry Act (2019), allows commercial uses of the hemp plant, and a bill was introduced in February 2021 by Cate Faehrmann that would legalise cannabis products in New South Wales.
Cannabis exports may also be a bright spot — shipping the drug out of the country was legalised in 2018, and top markets now include countries like Germany, the UK and South Africa.
Notably, Australia has expressed its desire to become one of the largest international cannabis suppliers. Back in 2018, former Health Minister Greg Hunt said, “We’d like to be potentially the world’s number one supplier.”
A 2020 report from Prohibition Partners forecasts that medical cannabis in the Oceania region, which includes Australia, could be worth US$600 million by 2024, while recreational cannabis could rake in US$1.55 billion.
The report also says that, despite the double-digit fall of cannabis stock prices in Australia (attributed partially to the COVID-19 pandemic), production and supply lines for the local cannabis industry have been maintained.
Peter Comerford, CEO of Australia healthcare product wholesaler Anspec, said the country is in a solid position to “capitalise on whichever aspects of this new industry that it chooses.”
Investing in cannabis stocks on the ASX: How to get started
The universe of ASX-listed cannabis stocks is small, but there are certainly options for investors willing to do a little research. To get started, check out these lists on the topic:
Investing in cannabis stocks on the ASX: Investor takeaway
Though Australia's cannabis industry is still in its early stages, increased patient numbers and a push toward recreational cannabis use could open the market to novel investment opportunities.
The nation's expanding cannabis export space could also further the growth of its place in the global cannabis market. For now, there's time for interested investors to get in early and gain a toehold.
This is an updated version of an article first published by the Investing News Network in 2019.
Don’t forget to follow us @INN_Australia for real-time news updates!
Securities Disclosure: I, Ryan Sero, hold no direct investment interest in any company mentioned in this article.
- What Australian Political Parties Think About Cannabis | INN ... ›
- Australian Cannabis Outlook 2022: Positive Signs for Sales and ... ›
- What Investors Should Know About CBD in Australia - Investing News Australia ›
- Hemp Investing in Australia - Investing News Australia ›
- Top 3 ASX Cannabis Stocks (Updated January 2022) - Investing News Australia ›
VIDEO — Will Rhind: Upside Favors Gold; Strong US Dollar Checking Gains for Now
Is there more upside right now for gold or the US dollar? "I think clearly I'm in the camp of favoring gold on that one," said Will Rhind of GraniteShares.
Will Rhind: Upside Favors Gold; Strong US Dollar Checking Gains for Now youtu.be
Strength in the US dollar is keeping the gold price in check right now, but that won't last forever.
Speaking to the Investing News Network, Will Rhind, CEO of GraniteShares, said the yellow metal is in a good position given market conditions and looks set to strengthen moving forward.
"(Gold has) really managed to shrug off a lot of the negatives around rising rates and a strong dollar, and I think people have got to ask themselves, 'How much more can the dollar strengthen from here? ... Realistically is there more upside for the dollar here, or for gold?' I think clearly I'm in the camp of favoring gold on that one," he said.
As the dollar puts downside pressure on gold, inflation is providing support for the precious metal, and despite the US Federal Reserve's efforts, Rhind doesn't see a quick end to rising prices.
"We like to talk about (inflation) as one simple construct, but there is inflation that perhaps the Fed is more in control of and there's inflation that the Fed is much less in control of," he explained.
"I think in some respects it's kind of an unreasonable ask of the Fed to (try to control inflation) given that again there are some things that maybe they ... have more control over than others."
When asked if a recession is in the cards, Rhind referred back to historical precedent.
"I think in history we've never had an environment where inflation's been above I think 4.5 percent and it's been able to be brought down below that number without causing a recession," he explained. "So certainly the probability leans much more towards there being a recession."
Watch the interview above for more from Rhind on gold, as well as on the overall commodities sector.
Don't forget to follow us @INN_Resource for real-time updates!
Securities Disclosure: I, Charlotte McLeod, hold no direct investment interest in any company mentioned in this article.
Editorial Disclosure: The Investing News Network does not guarantee the accuracy or thoroughness of the information reported in the interviews it conducts. The opinions expressed in these interviews do not reflect the opinions of the Investing News Network and do not constitute investment advice. All readers are encouraged to perform their own due diligence.
Hygrovest Limited (ASX:HGV) ("HGV") is an Australian-listed specialist investment company which concentrates on producing capital growth for shareholders over the medium term from investments in listed and unlisted equities and other financial assets.
HGV agrees to divest its investment in Entourage Health above current book value
HGV has agreed to support proposed changes to the terms of the unsecured convertible debentures issued by Entourage Health Corp (ENT or the Company) which would allow HGV to divest its investment in ENT convertible debentures (the Notes).
The attached release by ENT details the changes proposed by the Company which would allow HGV to complete the divestment of ENT which bring forward the maturity date from 25 September 2022 to 30 June 2022 and reduce the redemption percentage from 100% to 60% of face value (the Note Proposals).
The Company has announced that a meeting of ENT Noteholders will be held in late June 2022 to consider the Note Proposals. HGV has signed a voting agreement to vote in favour of the changes. If the meeting of ENT Noteholders approves the amendments, ENT will redeem HGV’s Notes for CAD3.6m plus accrued interest on or around 30 June 2022 which is a premium to HGV’s book value of CAD2.5m as at 30 April 2022.
On the basis that ENT Noteholders approve the resolutions, HGV will have generated a loss of 18% on the original investment (after inclusion of cash interest received). Whilst the investment in HGV’s Notes has been well below expectations at the time of initial investment, it should be noted that the return is materially above that for the listed Canadian cannabis sector which has declined approximately 70%1 since January 2020.
The divestment was negotiated by HGV’s asset manager, Parallax Ventures Inc, on behalf of HGV.
“The divestment of HGV’s investment in ENT at a significant premium to our book value is an important step in realising HGV’s underperforming cannabis investments and applying those funds to sectors which have higher growth prospects” said Mr Wall, HGV’s Chairman.
HGV made its initial investment in ENT in September 2019 and now has a current book value of CAD2.5m comprising:
- CAD6m in 8.5% unsecured Convertible Debenture units issued by ENT which HGV has the option to convert into 3.75m shares by the maturity date of 25 September 2022. The debenture units have preference over ordinary shares with interest paid to HGV on a six-monthly basis. The market value of the notes is calculated by multiplying the CAD6m by the market price divided by 100.
- Listed Warrants that allow HGV to acquire an additional 3.75m shares for CAD1.80 each by 25 September 2022.
VIDEO - Green Technology Metals: Cashed Up and Pursuing Low-carbon Lithium in Ontario
General Manager Matt Herbert described Ontario as an “undiscovered gem,” and spoke about the company’s work on its lithium projects in the province.
After making its ASX debut this past November, Green Technology Metals (ASX:GT1) has been hard at work in Ontario, Canada, where it holds three projects covering 35,000 hectares.
Speaking to the Investing News Network at the Prospectors & Developers Association of Canada (PDAC) convention, General Manager Matt Herbert described the province as an “undiscovered gem” with the potential to contribute to the lithium supply chain in an environmentally conscious manner.
“I think the opportunity there is to create some very, very green lithium,” he said.
“At the moment, a lot of lithium is mined in Western Australia, (then) shipped to China for processing; from China it goes to European battery markets. I think by the time that lithium arrives where it’s supposed to arrive it’s left itself a bit of a carbon footprint,” Herbert explained during the conversation. “We have a real opportunity here to leverage low-carbon lithium in a place that is really screaming for security.”
Green Technology Metals has already seen support from members of the Ontario government, including recently re-elected Premier Doug Ford, and Greg Rickford, who is the province’s minister of northern development, mines, natural resources and forestry, as well as its minister of indigenous affairs.
“Both are massive supporters of critical minerals,” said Herbert. “Those things are important when you’re at the permitting and approval stage, and that’s exactly where we’re at. We’re able to leverage those relationships really well, and there’s just no better place to be at the moment.”
Watch the interview above for more from Herbert on Green Technology Metals and its plans for the next six months. You can also click here for our recap of PDAC, and here for our full PDAC playlist on YouTube.
Don’t forget to follow us @INN_Australia for real-time updates!
Securities Disclosure: I, Charlotte McLeod, hold no direct investment interest in any company mentioned in this article.
Editorial Disclosure: Green Technology Metals is a client of the Investing News Network. This article is not paid-for content.
The Investing News Network does not guarantee the accuracy or thoroughness of the information reported in the interviews it conducts. The opinions expressed in these interviews do not reflect the opinions of the Investing News Network and do not constitute investment advice. All readers are encouraged to perform their own due diligence.
VIDEO — Green Technology Metals: Cashed Up and Pursuing Low-carbon Lithium in Ontario
General Manager Matt Herbert described Ontario as an "undiscovered gem," and spoke about the company's work on its lithium projects in the province.
Green Technology Metals: Cashed Up and Pursuing Low-carbon Lithium in Ontario youtu.be
After making its ASX debut this past November, Green Technology Metals (ASX:GT1) has been hard at work in Ontario, Canada, where it holds three projects covering 35,000 hectares.
Speaking to the Investing News Network at the Prospectors & Developers Association of Canada (PDAC) convention, General Manager Matt Herbert described the province as an "undiscovered gem" with the potential to contribute to the lithium supply chain in an environmentally conscious manner.
"I think the opportunity there is to create some very, very green lithium," he said.
"At the moment, a lot of lithium is mined in Western Australia, (then) shipped to China for processing; from China it goes to European battery markets. I think by the time that lithium arrives where it's supposed to arrive it's left itself a bit of a carbon footprint," Herbert explained during the conversation. "We have a real opportunity here to leverage low-carbon lithium in a place that is really screaming for security."
Green Technology Metals has already seen support from members of the Ontario government, including recently re-elected Premier Doug Ford, and Greg Rickford, who is the province's minister of northern development, mines, natural resources and forestry, as well as its minister of indigenous affairs.
"Both are massive supporters of critical minerals," Herbert said. "Those things are important when you're at the permitting and approval stage, and that's exactly where we're at. We're able to leverage those relationships really well, and there's just no better place to be at the moment."
Watch the interview above for more from Herbert on Green Technology Metals and its plans for the next six months. You can also click here for our recap of PDAC, and here for our full PDAC playlist on YouTube.
Don't forget to follow us @INN_Australia for real-time updates!
Securities Disclosure: I, Charlotte McLeod, hold no direct investment interest in any company mentioned in this article.
Editorial Disclosure: Green Technology Metals is a client of the Investing News Network. This article is not paid-for content.
The Investing News Network does not guarantee the accuracy or thoroughness of the information reported in the interviews it conducts. The opinions expressed in these interviews do not reflect the opinions of the Investing News Network and do not constitute investment advice. All readers are encouraged to perform their own due diligence.
- John Kaiser: Lithium Juniors are the Future of the EV Story ›
- What Do Lithium Experts Think About Goldman Sachs Oversupply ... ›
- Best 5 ASX Lithium Stocks of 2022 - Investing News Australia ›
Top News
FEATURED STOCKS
Global News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.